federal_register: 2017-27124
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-27124 | Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments; Draft Guidance for Industry; Availability | Notice | The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Information Requests and Discipline Review Letters Under GDUFA." This draft guidance explains how FDA will issue and use an information request (IR) and/or a discipline review letter (DRL) during the review of an original abbreviated new drug application (ANDA). | 2017-12-18 | 2017 | 12 | https://www.federalregister.gov/documents/2017/12/18/2017-27124/information-requests-and-discipline-review-letters-under-the-generic-drug-user-fee-amendments-draft | https://www.govinfo.gov/content/pkg/FR-2017-12-18/pdf/2017-27124.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Information Requests and Discipline Review Letters Under GDUFA." This draft guidance explains how FDA will issue and use an... |